D. E. Shaw & Co., Inc. Immatics N.V. Transaction History

D. E. Shaw & Co., Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$3.5 - $6.14 $61,848 - $108,499	-17,671 Reduced 59.98%	11,792 $63,000
Q1 2025 May 15, 2025	BUY	$4.18 - $7.42 $19,767 - $35,089	4,729 Added 19.12%	29,463 $132,000
Q4 2024 Feb 14, 2025	SELL	$6.73 - $11.21 $261,884 - $436,214	-38,913 Reduced 61.14%	24,734 $175,000
Q3 2024 Nov 14, 2024	BUY	$10.93 - $12.92 $695,661 - $822,319	63,647 New	63,647 $726,000

93M

53.8K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $778M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.